Skip to main content
. 2009 Feb 9;27(8):1168–1176. doi: 10.1200/JCO.2008.18.1024

Fig 3.

Fig 3.

Forest plot of covariate adjusted hazard ratios (HR) for disease-free survival in patients in the luminal A and luminal B groups by treatment (hazard ratios and 95% CIs using fluorouracil, doxorubicin, and cyclophosphamide and no tamoxifen as baseline treatments). Values less than 1 show an advantage to docetaxel, doxorubicin, and cyclophosphamide (TAC) or tamoxifen.